The Intervention of Multi-vitamin With Minerals to Hyperuricemia

Effect of Multi-vitamins With Minerals on Uric Acid Metabolism in Subjects With Hyperuricemia: A Randomized, Double-blinded, Placebo-controlled Trail

To evaluate the validity of multi-vitamin-and-minerals intervention on uric acid metabolism in hyperuricemic adults.

Study Overview

• Status: Unknown
• Conditions: Hyperuricemia
• Intervention / Treatment: Combination product: High-dose multi-vitamins with minerals; Combination product: Low-dose multi-vitamins with minerals; Combination product: Hypouricemic tablets; Combination product: Placebo

Detailed Description

Hyperuricemia is a type of metabolic diseases which caused by purine metabolic disorder and (or) uric acid excretion disorder. Uric acid is produced by cell metabolism and food purine metabolism as the end-point product. Excess alcohol and purine-rich food intake together with abnormal function of purine metabolic key enzyme are the main causes leading increasing serum level of uric acid. It has been a focus in nutritional area that a safer approach of preventing hyperuricemia by adjustment of nutritional intake. Primary studies found that proper supplement of microelements showed significant regulations in inflammation and oxidative stress induced by elevating level of uric acid. Therefore, this study will be conducted to test whether the supplement of multi-vitamins with minerals will lower the level of blood uric acid and improve the imbalance of microelement metabolism or not. The investigators will recruit 200 subjects of study who would be divided into four groups and accept intervention of high-dose multi-vitamins with minerals, low-dose multi-vitamins with minerals, hypouricemic tablets and placebo, respectively. After intervention of 3 or 6 months, serum uric acid and purine metabolism function will be detected. This study could provide references for illuminating the mechanism in purine metabolism and nutritional measures to control the pathological development of hyperuricemia.

• Study Type: Interventional
• Enrollment (Anticipated): 200
• Phase: Phase 4

Contacts and Locations

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510080
      • Recruiting
      • Sun Yat-sen University
      • Contact: Yi Guo, Ph.D; Email: guoyi_019@126.com
      • Contact: Min Xia, Ph.D; Email: xiamin@mail.sysu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 22 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Under the dietary pattern of normal intake of purine, the level of serum uric acid is higher than 420μmol/L for male or 360μmol/L for female (not be detected twice at the same day).

Exclusion Criteria:

• Gouty arthritis, tophus or gouty nephropathy.
• Complications including diabetes, cardiovascular diseases (angina, myocardial infarction) and so on.
• Taken hypouricemic medicine in the last week before intervention, including allopurinol, benzbromarone, probenecid and so on.
• Had an operation in the past year.
• Malnutrition or severe obesity, BMI<18.5kg/m2 or >30.0 kg/m2.
• Mental diseases, tumor, hepatic cirrhosis or other diseases that may interfere with the intervention.
• Alcohol abuse (>80g/d)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: High-dose multi-vitamins with minerals; Generic name: High-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months	Combination product: High-dose multi-vitamins with minerals; The high-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.37mg,vitamin C 0.27mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
Experimental: Low-dose multi-vitamins with minerals; Generic name: Low-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months	Combination product: Low-dose multi-vitamins with minerals; The low-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.20mg,vitamin C 0.50mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
Active Comparator: Hypouricemic tablets; Generic name: Hypouricemic tablets Dosage form: Capsule Frequency: Six pills daily for 3 months	Combination product: Hypouricemic tablets; The hypouricemic tablets contained skipjack,salvia and rosemary extract.
Placebo Comparator: Placebo; Generic name: Placebo Dosage form: Capsule Frequency: Two pills daily for 6 months	Combination product: Placebo; The placebo tablets contained maltodextrin and tartrazine.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum uric acid	Level of uric acid was described in μmol/L	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum IL-1	Inflammation condition，serum IL-1 was described in ng/l.	1.5 years
Serum IL-6	Inflammation condition, level of IL-6 was described in ng/l	1.5 years
Serum IL-10	Inflammation condition, level of IL-10 was described in ng/l	1.5 years
Serum TNF-α	Inflammation condition, level of TNF-α was described in ng/l	1.5 years
Serum CRP	Inflammation condition, level of CRP was described in mg/l	1.5 years
Serum c-peptide	Pancreas islets function, c-peptide was described in nmol/L.	1.5 years
Serum xanthine oxidase(XOD) activity	Purine metabolism function, XOD activity was described in in U/ml.	1.5 years
Serum phosphoribosyl pyrophosphate(PRPP)	Purine metabolism function, PRPP level was described in μmol/g Hb.	1.5 years
Serum Glutamine(Glu)	Purine metabolism function, Glu level was described in μmol/L.	1.5 years

Collaborators and Investigators

• Sponsor: Sun Yat-sen University
• Investigators: Principal Investigator: Min Xia, Ph.D, Department of Nutrition,School of Public Health,Sun Yat-sen University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2017
• Primary Completion (Anticipated): January 1, 2018
• Study Completion (Anticipated): April 1, 2018

Study Registration Dates

• First Submitted: March 22, 2017
• First Submitted That Met QC Criteria: July 13, 2017
• First Posted (Actual): July 14, 2017

Study Record Updates

• Last Update Posted (Actual): July 14, 2017
• Last Update Submitted That Met QC Criteria: July 13, 2017
• Last Verified: July 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Hyperuricemia; Physiological Effects of Drugs; Micronutrients; Vitamins
• Other Study ID Numbers: ZXYZM-6

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: Do not share participants data

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No